Retifanlimab

Retifanlimab

Retifanlimab is a humanized, hinge-stabilized IgG4κ anti-PD-1 antibody that is currently being developed as a treatment for various tumor types, including squamous cell carcinoma of the anal canal (SCAC), non-small cell lung cancer (NSCLC), and gastric cancer. It is an investigational PD-1 inhibitor that has been shown to be safe and effective as monotherapy in previously treated metastatic SCCA.From: Antibodies to watch in 2023 [2023], Safety considerations with new treatment regimens for anal cancer [2021]

Antibody-Based Therapies

View Chapter

Purchase Book

Published in David E. Thurston, Ilona Pysz, Chemistry and Pharmacology of Anticancer Drugs, 2021

David E. Thurston, Ilona Pysz

A number of examples of PD-1-targeted antibodies are described below. Nivolumab (Opdivo™), pembrolizumab (KeytrudaTM), and cemiplimab (LibtayoTM) are approved by the FDA and many other other Western countries, while toripalimab (TuoyiTM), tislelizumab, sintilimab (Tyvyt™), and camrelizumab have been approved (conditionally in some cases at the time of writing) by the Chinese FDA. Several other PD-1-targeted antibodies are at various stages of clinical development for a wide range of hematological and solid tumor indications but are not discussed any further here. These include spartalizumab (PDR001; Novartis), dostarlimab (TSR-042, WBP-285; GlaxoSmithKline), retifanlimab (INCMGA00012, MGA012; Incyte and MacroGenics), AMP-224 (AstraZeneca/MedImmune and GlaxoSmithKline), and AMP-514 (MEDI0680; AstraZeneca).

Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents

View Article

Journal Information

Published in Expert Opinion on Drug Discovery, 2022

Martin Perez-Santos, Maricruz Anaya-Ruiz, Luis Villafaña-Diaz, Gabriela Sánchez Esgua

NCT04370704 is a phase 1–2, open label, and two-arms study designed to evaluate the safety and tolerability of the combinations INCAGN02385/INCAGN02390 (anti-TIM-3 antibody) and INCAGN02385/INCAGN02390/Retifanlimab (anti-PD-1 antibody) in patients with melanoma. NCT05287113 is a phase, open label, multicenter, three-arms study that will evaluate the safety and efficacy of the combination of retifanlimab/INCAGN02385 and retifanlimab/INCAGN02385/INCAGN02390 in patients with squamous cell carcinoma of the head and neck.

Explore chapters and articles related to this topic

Antibody-Based Therapies

Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents